Your implication is that the task force did not recommend Remdesivir because there is not data behind it's use. This is not correct.
Remdesivir is in EXTREMELY limited production and Gilead is passing it over to only selected hospital pharmacies. Before this, it was "compassionate care" use only and literally had to be shipped one treatment at a time to the prescribing physician.
The data, actually, are far better for Remdesivir (both efficacy and side-effect profile) than HCQ.
The underlying problem is this is an investigational medicine, and there simply is not that much of it out there. It's made in batches, then stored for clinical trials, so that everyone in the trial gets the drug from the same batch (i.e. remove one variable that could confound the results).
HCQ has been around for 40+ years, it's easy to make, and it out there because it is used for other conditions.
The recommendation was made because of relative availability, nothing more, nothing less.